Floatz logo

Idarubicine

Lymphoblastic Lymphoma

St. Jude Children's Research HospitalPhase 3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

53 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
VINDESINE
University Hospital Muenster
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →